ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2027

Clinical Features and Treatment of Retroperitoneal Fibrosis in a Referral Hospital and Literature Review

Adrián Martín-Gutiérrez1, Javier Loricera2, Fernando Lopez-Gutierrez3 and Ricardo Blanco-Alonso4, 1Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 4Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

Meeting: ACR Convergence 2024

Keywords: Fibrosing syndromes, glucocorticoids, IgG4 Related Disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Retroperitoneal fibrosis (RPF) is usually idiopathic (iRPF), but may be secondary to drugs, neoplasms, infections, or may be part of an IgG4-related disease.
Our aim was to evaluate the clinical features, analytical features, imaging findings and treatment modalities in patients with RPF.

Methods: Patients diagnosed with RPF in a referral hospital between 2000 and 2023. For the literature review, we searched PubMed and the Cochrane library from its inception until 31 December 2023, selecting those series with the largest number of patients.

Results: We present 26 patients (11 females/15 males) with RPF. The mean±SD age of the patients at diagnosis was 59.7±12.4 years. Seventeen patients had an iRPF. In the remaining 9 patients, RPF was secondary to: neoplasia (n=5; 19%), radiotherapy (n=2; 8%), acute pancreatitis (n=1; 4%), IgG4-related disease (n=1; 4%). The main characteristics of the patients are listed in the Figure 1. Fifty percent of the patients were smokers or ex-smokers. Abdominal pain (65%) and low back pain (42%) were the most frequent manifestations. Elevation of acute phase reactants was observed in 15/20 (75%) patients and worsening renal function in 10/25 (40%) patients. In the literature review, 4 series of more than 50 patients each were selected. The main data from the different series are listed in Figure 1. The diagnosis of RPF was made by ultrasounds (n=16; 61%), CT (n=24; 92%), MRI (n=2; 8%), PET/CT (n=6; 23%). The most frequent pattern of involvement was periaortic-periiliac (50%) and hydronephrosis (50%) (Figure 2A). Glucocorticoids were the most frequent medical treatment (69%). The most frequent interventional procedure was ureteral stenting (38%) (Figure 2B).

Conclusion: RPF is a rare entity that may be idiopathic or secondary to other processes. Abdominal pain and abdominal pain are frequent manifestations. Glucocorticoids are the medical treatment of choice and ureteral stenting is the most commonly used interventional procedure.

Supporting image 1

Abbreviations: CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, IQR: interquartile range, ND: no data, RPF: retroperitoneal fibrosis, SD: standard deviation.

Supporting image 2


Disclosures: A. Martín-Gutiérrez: None; J. Loricera: AstraZeneca, 2, 6, Celgene, 2, 6, Eli Lilly, 5, Janssen, 5, Merck/MSD, 2, 5, 6, Novartis, 12, Formation/Congress attendance, Pfizer, 5, Roche, 2, 5, 6, UCB, 2, 5, 6; F. Lopez-Gutierrez: AstraZeneca, 12, Formation/Congress attendance, 12, Formation/Congress attendance, Novartis, 12, Formation/congress attendance; R. Blanco-Alonso: AbbVie, 2, 5, 6, Bristol-Myers Squibb, 2, 6, Galapagos, 6, Janssen, 2, 6, Lilly, 2, 6, MSD, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 5, 6.

To cite this abstract in AMA style:

Martín-Gutiérrez A, Loricera J, Lopez-Gutierrez F, Blanco-Alonso R. Clinical Features and Treatment of Retroperitoneal Fibrosis in a Referral Hospital and Literature Review [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/clinical-features-and-treatment-of-retroperitoneal-fibrosis-in-a-referral-hospital-and-literature-review/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-features-and-treatment-of-retroperitoneal-fibrosis-in-a-referral-hospital-and-literature-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology